Regen BioPharma Inc (RGBP)

[cvinvestor]

On the optimistic side, we are 20 trading days or less from the release of the full audited CRL report on HemaX which we expect to be positive (no indication it would be otherwise) and then only another 20 or so trading days until FDA approval followed by official Orphan Drug Status for HemaX.

With CRL doing the experiments, we don't have the worry of further delays or the experiments not being done right and with Dr. Kesari pursuing the dCellVax issues and experimental data, we won't have to wait another 2 years for dCellVax to move forward.

Success breeds success and as long as Koos allows the company to gain in value outside of himself, we should also benefit for our long term investments.